Abstract:Objectives: Previous studies reported that autophagy is activated in human dilated cardiomyopathy (DCM). It is still unknown whether modulating autophagy can improve cardiac function of the failing heart. Methods: We immunized rats with porcine cardiac myosin to set up a model of DCM. Rapamycin, a kind of mTOR inhibitor upregulating autophagy, was given to rats weeks after the immunization at low (1 mg/kg . day i.p.), intermediate (2 mg/kg . day i.p.) and high dose (4 mg/kg . day i.p.) for 2 weeks. Results: Compared to the control group (ejection fraction, EF = 81.3 +/- 3.8%), the average EF decreased in both the DCM group (EF = 56.1 +/- 3.3%) and the high-dose rapamycin group (EF = 55.9 +/- 3.6%), but recovered in the low-/intermediate-dose rapamycin groups (EF = 64.9 +/- 4.6/69.4 +/- 4.4%). Phosphorylation of p70s6k and 4E-BP1 decreased and the expression of LC3BI/II increased in all rapamycin groups. Autophagic vacuoles were easily found in these groups. However, body weight was significantly reduced in the rapamycin groups. Furthermore, mortality was increased in the high-dose rapamycin group. Conclusions: Rapamycin could improve cardiac function of early-stage DCM, but the effect of rapamycin turned out to be biphasic and the effective range appeared narrow. Copyright (C) 2013 S. Karger AG, Basel

Modulating autophagy improves cardiac function in a rat model of early-stage dilated cardiomyopathy.